Haloperidol is widely considered a reference standard in antipsychotic
therapy and is commonly used in comparative studies of the efficacy a
nd safety of antipsychotic medication Comparative clinical trials have
shown that the novel antipsychotic agent risperidone tends to have gr
eater efficacy lie, clinical response defined as a greater than or equ
al to 20% reduction in total scores on the Positive and Negative Syndr
ome Scale) than haloperidol in patients with chronic schizophrenia and
poses less risk of extrapyramidal symptoms (EPS). We used DerSimonian
and Laird's random-effects model to analyze pooled patient data from
available randomized, double-masked, comparative trials of risperidone
and haloperidol in patients with schizophrenia treated for at least 4
weeks al recommended doses. The purpose of the analysis was to determ
ine whether there are significant overall differences in the rates of
patient clinical response, prescription of anticholinergic agents, and
treatment dropout. Six of the nine trials revealed in a literature se
arch met all criteria for inclusion in the meta-analysis. The meta-ana
lysis showed that in patients with chronic schizophrenia, risperidone
therapy is associated with significantly higher response rates, signif
icantly less prescribing of anticholinergic medication, and significan
tly lower treatment dropout rates than haloperidol. These results demo
nstrate the greater treatment efficacy associated with risperidone com
pared with haloperidol and suggest both a lower incidence of EPS and i
mproved treatment compliance.